A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes

OBJECTIVE: The aim of this study was to investigate the pharmacokinetic, pharmacodynamic and safety profile of the glucagon‐like peptide‐1 receptor agonist, lixisenatide, for the treatment of type 2 diabetes (T2D) in pediatric individuals. MATERIALS AND METHODS: In this Phase 1, multicenter, randomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Barrientos‐Pérez, Margarita, Hsia, Daniel S., Sloan, Lance, Nell, Haylene, Mungur, Ounisha, Hovsepian, Lionel, Schmider, Wolfgang, Spranger, Robert, Yang, Na, Niemoeller, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons A/S 2022
Materias:
Obesity/Insulin Resistance, Type 2 Diabetes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790255/
https://www.ncbi.nlm.nih.gov/pubmed/35411611
http://dx.doi.org/10.1111/pedi.13343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790255/
https://www.ncbi.nlm.nih.gov/pubmed/35411611
http://dx.doi.org/10.1111/pedi.13343

Ejemplares similares